This article is part of the Topical Collection on Metabolism Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
Picrosirius red and Oil Red O staining
Semaglutide For Neurodegenerative Disease Neurodegenerative diseases include a group of progressive and complex conditions, including Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS), etc
NCT03819153), secondary analyses of GLP-1RA CVOTs indicate that liraglutide [17], semaglutide [18], dulaglutide [25] and efpeglenatide [20] may reduce the relative risk of a composite kidney outcome, comprising new-onset macroalbuminuria, worsening kidney function, end-stage renal disease and renal death, by 1536%
